ISN Webinar: Semaglutide’s Impact on Kidney Disease and Cardiovascular Outcomes in Type 2 Diabetes: Insights from the FLOW Study

Join us for an insightful webinar hosted by the International Society of Nephrology (ISN) focusing on the recent results from the phase FLOW trial, which evaluated the effects of semaglutide on kidney disease and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).

The FLOW trial (ClinicalTrials.gov Identifier: NCT03819153) was a randomized, double-blind, parallel-group, placebo-controlled study involving 3533 participants with type 2 diabetes and CKD. The trial assessed the effects of semaglutide 1mg compared to placebo on kidney outcomes, including progression of renal impairment and risk of renal and cardiovascular mortality.Key results showed that treatment with semaglutide 1mg significantly reduced the risk of kidney disease progression, cardiovascular events, and mortality by 24% compared with placebo. These findings underscore the potential of semaglutide to become the first GLP-1 receptor agonist treatment option for individuals with type 2 diabetes and CKD.

Dr. Katherine Tuttle and Dr. Vlado Perkovic, esteemed nephrology experts, will delve into the major efficacy outcomes, including the time to first occurrence of a composite primary endpoint event, the impact on eGFR, and the reduction in major adverse cardiovascular events and all-cause mortality.

Learning Objectives:

- To present the key findings of the FLOW trial, highlighting the significant reduction in kidney disease-related events with semaglutide treatment.
- To discuss the implications of these findings for clinical practice, particularly for the management of patients with type 2 diabetes and CKD.
- To explore the potential for semaglutide as a novel GLP-1 treatment option for this patient population.

Roberto Pecoits-Filho

USA

Dr. Pecoits-Filho is a Senior Research Scientist at Arbor Research Collaborative for Health in Michigan, USA and a Professor of Medicine, Pontifical Catholic University of Paraná in Curitiba, Brazil. He is the current (2021-23) Chair of the Education Committee of the International Society of Nephrology. As a clinician, he has broad activities in Internal Medicine and Nephrology based at the University affiliated hospitals, where he was the Chief of the Department of Internal Medicine between 2010 and 2016, the Director of the Residency program in Nephrology from 2013 to 2016. Dr. Pecoits-Filho is the Principal Investigator for the study CKDOPPS, a multinational study on practice patterns and outcomes in chronic kidney disease and act as a Scientific Leader for clinical trials in the Americas with George Clinical. Dr. Pecoits-Filho received his MD and trained in Internal Medicine and Nephrology in Curitiba, Brazil before completing a nephrology research fellowship at the University of Missouri, Columbia and a PhD from the University of Sao Paulo. He was a visiting scholar for extended periods at the Karolinska Institute (Sweden) and the George Institute (Australia), and has participated as a principal investigator, regional leader and in steering committees in multinational clinical trials. Dr. Pecoits-Filho served as a member of the Executive Committee of the International Society of Nephrology (ISN) (2017-2019), the SONG Initiative (2017-present) and KDIGO (2016-2018).